CompoAtlas

Optimal Floral Plus

On sale on the US market (according to the DSLD)

OHS Optimal Health Systems, food supplement from the US market

Optimal Floral Plus (OHS Optimal Health Systems), a food supplement without a usable barcode in DSLD, is described by its US market label. The French and European rules we can apply to this label flag no particular point. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

If this product were sold in France

No point flagged by the rules we apply.

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
OHS Optimal Health Systems
Barcode
Not provided or invalid in DSLD
Form
Capsule
One serving
3 capsules
Servings
up to 1 serving per day
Other ingredients (in English, as written)
Rice Flour, Hypromellose, Rice hull concentrate, Magnesium Stearate, Zinc, Copper, Manganese
Ingredient (as written, in English)CategoryPer serving
Optimal Flora BlendBlendnot stated
Lactobacillus plantarumMicro-organismnot stated
Lactobacillus acidophilus DDS-1Micro-organismnot stated
Bacillus coagulansMicro-organismnot stated
Lactobacillus bulgaricusMicro-organismnot stated
Bifidobacterium bifidumMicro-organismnot stated
Lactobacillus salivariusMicro-organismnot stated
Lactococcus lactisMicro-organismnot stated
Streptococcus thermophilusMicro-organismnot stated
Bifidobacterium animalis lactisMicro-organismnot stated
Jerusalem Artichoke (Helianthus tuberosus)Plant100 mg
Opti-Blend Delivery SystemBlend20 mg
AmylaseEnzymenot stated
Protease IEnzymenot stated
Protease IIEnzymenot stated
Serratia PeptidaseEnzymenot stated
LipaseEnzymenot stated
InvertaseEnzymenot stated
CellulaseEnzymenot stated
LactaseEnzymenot stated
Malt DiastaseEnzymenot stated
PhytaseEnzymenot stated
MolassesPlantnot stated

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Serratia Peptidase
    Read the warning, when it applies and the studies cited

    SERRAPEPTASE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gastrointestinal lesions/ulcers, a kidney or liver disorder, or are having surgery (Bhagat et al. 2013; Chopra et al. 2009; Al- Khateeb and Nusair 2008; Mazzone et al. 1990).

    Sources cited by Health Canada (4)
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
    • Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
    • Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
    • Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or anti-inflammatory medications (Bhagat et al. 2013; Chopra et al. 2009; Al-Khateeb and Nusair 2008; Mazzone et al. 1990).

    Sources cited by Health Canada (4)
    • Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
    • Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
    • Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial

    Known adverse reactions

    Stop use if rash, difficulty breathing, hypersensitivity and/or severe allergy occur (Bhagat et al. 2013; Balagi 2007).

    Sources cited by Health Canada (1)
    • Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 25 July 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : OHS Optimal Health Systems

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Optimal Floral Plus (OHS Optimal Health Systems): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/dsld-278270-optimal-floral-plus-ohs-optimal-health-systems, updated 24 October 2022.

List recorded in 2022. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line